Cargando…

Generation of a selectively cytotoxic fusion protein against p53 mutated cancers

BACKGROUND: A significant number of cancers are caused by defects in p21 causing functional defects in p21 or p53 tumour-suppressor proteins. This has led to many therapeutic approaches including restoration by gene therapy with wild-type p53 or p21 using viral or liposomal vectors, which have toxic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kousparou, Christina A, Yiacoumi, Efthymia, Deonarain, Mahendra P, Epenetos, Agamemnon A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503689/ https://www.ncbi.nlm.nih.gov/pubmed/22862878 http://dx.doi.org/10.1186/1471-2407-12-338

Ejemplares similares

The Secret Role of microRNAs in Cancer Stem Cell Development and Potential Therapy: A Notch-Pathway Approach
por: Prokopi, Marianna, et al.
Publicado: (2015)

Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins.
por: Deonarain, M. P., et al.
Publicado: (1998)

Targeting enzymes for cancer therapy: old enzymes in new roles.
por: Deonarain, M. P., et al.
Publicado: (1994)

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1
por: Pericleous, L M, et al.
Publicado: (2005)

Cas9 activates the p53 pathway and selects for p53-inactivating mutations
por: Enache, Oana M., et al.
Publicado: (2020)

Mechanistic insights into p53‐regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells
por: Marx, Christian, et al.
Publicado: (2021)

A recombinant single chain antibody interleukin-2 fusion protein.
por: Savage, P., et al.
Publicado: (1993)

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
por: Skalniak, Lukasz, et al.
Publicado: (2018)

The p53 Modulated Cytotoxicity of Ophiocoma scolopendrina Polysaccharide Against Resistance Ovarian Cancer Cells
por: Amini, Elaheh, et al.
Publicado: (2019)

Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity
por: Menendez, Daniel, et al.
Publicado: (2022)

p53 mutation and expression in lymphoma.
por: Adamson, D. J., et al.
Publicado: (1995)

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
por: Williamson, Chris T, et al.
Publicado: (2012)

DHA/EPA (Omega-3) and LA/GLA (Omega-6) as Bioactive Molecules in Neurodegenerative Diseases
por: Kousparou, Christina, et al.
Publicado: (2023)

Involvement of Glutathione Depletion in Selective Cytotoxicity of Oridonin to p53-Mutant Esophageal Squamous Carcinoma Cells
por: Li, Yinchao, et al.
Publicado: (2020)

P53 mutations in gastric carcinomas.
por: Seruca, R., et al.
Publicado: (1992)

Human p53‐p51 (p53‐Related) Fusion Protein: A Potent BAX Transactivator
por: Ikawa, Shuntaro, et al.
Publicado: (1999)

p53 Dysregulation in Breast Cancer: Insights on Mutations in the TP53 Network and p53 Isoform Expression
por: Steffens Reinhardt, Luiza, et al.
Publicado: (2023)

Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes
por: Theobald, Matthias, et al.
Publicado: (1997)

Mutations in p53, p53 protein overexpression and breast cancer survival
por: Rossner, Pavel, et al.
Publicado: (2009)

DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.
por: De Feudis, P., et al.
Publicado: (1997)

Selective in vitro cytotoxicity effect of Drimia calcarata bulb extracts against p53 mutant HT-29 and p53 wild-type Caco-2 colorectal cancer cells through STAT5B regulation
por: Laka, K., et al.
Publicado: (2021)

Sex- and Mutation-Specific p53 Gain-of-Function Activity in Gliomagenesis
por: Rockwell, Nathan C., et al.
Publicado: (2021)

p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.
por: Mineta, H., et al.
Publicado: (1998)

Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
por: Vierboom, Michel P.M., et al.
Publicado: (1997)

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
por: Middleton, Fiona K., et al.
Publicado: (2018)

Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53
por: Umano, Y, et al.
Publicado: (2001)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

The Novel Fusion Proteins, GnRH-p53 and GnRHIII-p53, Expression and Their Anti-Tumor Effect
por: Jia, Peiyuan, et al.
Publicado: (2013)

Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells
por: Sioud, Mouldy, et al.
Publicado: (2015)

Increased expression and mutation of p53 in choroidal melanoma.
por: Tobal, K., et al.
Publicado: (1992)

PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium
por: Bienfait, Lucie, et al.
Publicado: (2018)

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
por: Aziz, Moammir H., et al.
Publicado: (2011)

Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis
por: Iwahashi, Naoyuki, et al.
Publicado: (2022)

p53MutaGene: an online tool to estimate the effect of p53 mutational status on gene regulation in cancer
por: Amelio, I, et al.
Publicado: (2016)

Detection of p53 mutations in precancerous gastric tissue
por: Morgan, C, et al.
Publicado: (2003)

p53 mutations in urinary bladder cancer
por: Berggren, P, et al.
Publicado: (2001)

Do Mutations Turn p53 into an Oncogene?
por: Pitolli, Consuelo, et al.
Publicado: (2019)

Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding
por: Scott, Nathan, et al.
Publicado: (2010)

Multi-Omic Analysis of Two Common P53 Mutations: Proteins Regulated by Mutated P53 as Potential Targets for Immunotherapy
por: Vadakekolathu, Jayakumar, et al.
Publicado: (2022)

Selective cytotoxicity of intracellular amyloid β peptide(1–42) through p53 and Bax in cultured primary human neurons
por: Zhang, Yan, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_2b75p65p3sbu2khuvcsua8gai6